Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2020 | Story Gcina Mtengwane and Andiswa Khumalo | Photo Scott sa ha Molefe (Scott Photography)
Gcina Mtengwane and Andiswa Khumalo
Gcina Mtengwane and Andiswa Khumalo believe economic vulnerability of women is a cause and a propellant of gender-based violence.

Gender-based violence can be understood as violence that is perpetuated as a result of normative role expectations associated with gender, power, and culture. It takes different forms. The most common forms are physical, emotional, psychological, verbal, domestic and socio-economic violence, to mention a few.

It is a profound, widespread, and pressing matter in South Africa and beyond its borders. In its entirety, gender-based violence is a threat to the economy, society, and humanity, as it creates emotional, social, and economic unrest that prohibits the growth and success of individuals, families, communities, and society as a whole. More than 30% of women in South Africa suffer from gender-based violence in the form of harassment, rape, femicide or domestic violence. Although women and young girls are the worst affected by gender-based violence, the term and act apply to both genders, including men and young boys.

Economic vulnerability of women

Notwithstanding the fact that gender-based violence happens to both genders, it is worth noting that women are the worst affected. There is a myriad of reasons for this. This article puts its focus on the economic vulnerability of women as both a cause and a propellant of gender-based violence. What we argue here is that there are structural socio-economic differentials that create and perpetuate the vulnerability of women to gender-based violence. We further posit that unless these vulnerabilities are addressed, gender-based violence will be a persistent problem for generations to come.

Our starting point is that women in South Africa generally have a higher unemployment rate than men. Additional to this, women struggle to ascertain livelihoods outside employment. This means that even in cases where women are employed, they will earn less than men. Furthermore, women also struggle to succeed in entrepreneurship. This can be associated with the ‘unpaid normative duties’ of child-rearing and household maintenance. This makes them vulnerable to abuse, as they cannot exercise their independent social and economic existence outside the confines and control of the male partner. It is worth noting that black African women are the most vulnerable, with an unemployment rate of more than 30%.

More worrying is that more than four out of every ten young females (15-34) are not in employment, education, or training (NEET). This further exacerbates the vulnerability context across all ages. Females consistently record a higher headcount; however, they remain behind in social, political, economic, and cultural matters. To amplify this, Statistics SA (2020) reports that 39,2% of female-headed households in South Africa do not have an employed member of the household.

Another point of concern is that there is a ‘social class and income link’ associated with gender-based violence. Gender-based violence is more prevalent among less-educated women than those with secondary education or higher. Additional to this, wealth/income is a key factor in the prevalence of gender-based violence. To that end, Statistics SA (2020) reported that the prevalence of physical and sexual violence decreased with the wealth quintile. In other words, the higher the wealth/income, the lower the prevalence of gender-based violence.

Overcoming economic vulnerability

Over and above all of this, the bigger question is, ‘how do we overcome the economic vulnerability that subjects poor women to gender-based violence?’ Here are a few contemplations:
1) Empowerment of women and economic justice. It may be good to take more deliberate and decisive action to capacitate women to a point where they are able to support their own livelihoods outside of economic dependence on a male.
2) Unlearning the outdated gender roles. Research suggests that more and more women are exiting the ‘nurturing and child-rearing’ role. This is because of the rising cost of living. Technology has made paid work less labour intensive. This then eliminates physical traits as a requirement for high-paying employment opportunities.
3) Socio-cultural re-engineering. This speaks to unlearning outdated cultural norms and dictates. While noting that every society, ethnic group, and culture has gender role expectations, these can also change over time. Perhaps now is the time for those expectations to change. If its existence is tantamount to abuse and even death, then certainly we need to unlearn the toxic and outdated and learn the forward-looking and solidarity-inducing doctrine.
4) Women as spearheads in women’s issues to inform legislation, policy, and practice. As the adage goes, ‘one is the master of your own condition’. This means that a person’s awareness of her/his condition allows them to be better suited to make the best inputs to liberate herself and those in like conditions.  

A lot more than what we suggest can be done to uplift women from the economic vulnerability that subjects them to gender-based violence in the household and elsewhere. We do not hold a monopoly on gender-based violence and the solutions therein. Our only hope is to spark a conversation that will contribute to feasible real-life solutions to one of our biggest and far-reaching challenges as a nation – gender-based violence and its socio-economic roots.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept